Plain-English translation of NCT06937229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people who completed earlier trials of xanomeline tartrate/trospium chloride ( and ), a new medication combination designed to treat agitation in Alzheimer's disease. The study will track how safe and effective this medication continues to be when used over the long term. Researchers want to understand whether the treatment remains well-tolerated and helpful as people take it for several months.
While earlier studies showed promise for this medication, doctors need to know whether it stays safe and effective over longer periods of time—just like people would actually take it in real life. This study gathers that important information to help determine if this medication could become a standard treatment option.
You likely qualify if…
You likely don't qualify if…
As a participant, you would continue taking the two-part medication (one immediate-release capsule and one enteric-coated capsule) that you began in the earlier study. You would visit the study site regularly so doctors can check how you're doing, monitor for any side effects, and see whether your agitation remains improved. Your caregiver would be involved in these visits and observations to help provide a complete picture of how the medication is working in your daily life.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States